SITE001-0303

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE001 (USA) · Dr. Reyes
consented 2023-02-23

AEs

Serious

Dropout signal

–

Adverse events

severe serious assessed

Grade 4 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-09-16 (study day 191); relationship: N; serious criteria: life-threatening

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-12-27 (study day 293); relationship: not assessed

severe serious assessed

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-01-08 (study day 305); relationship: not assessed; serious criteria: hospitalization

moderate assessed

Grade 2 Dyspnoea — outcome: UNKNOWN; onset 2024-03-24 (study day 381); relationship: not assessed

Data queries

No data queries.